These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 36196777)
1. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Knupp KG; Scheffer IE; Ceulemans B; Sullivan J; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Agarwal A; Lock M; Dai D; Farfel GM; Galer BS; Gammaitoni AR; Polega S; Davis R; Gil-Nagel A Epilepsia; 2023 Jan; 64(1):139-151. PubMed ID: 36196777 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial. Knupp KG; Scheffer IE; Ceulemans B; Sullivan JE; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Shore S; Agarwal A; Lock M; Farfel GM; Galer BS; Gammaitoni AR; Davis R; Gil-Nagel A JAMA Neurol; 2022 Jun; 79(6):554-564. PubMed ID: 35499850 [TBL] [Abstract][Full Text] [Related]
3. A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome. Lagae L; Schoonjans AS; Gammaitoni AR; Galer BS; Ceulemans B Epilepsia; 2018 Oct; 59(10):1881-1888. PubMed ID: 30146701 [TBL] [Abstract][Full Text] [Related]
4. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes. Frampton JE Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680 [TBL] [Abstract][Full Text] [Related]
5. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome. Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810 [TBL] [Abstract][Full Text] [Related]
6. Evaluating fenfluramine hydrochloride as an oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome. Besag FMC; Vasey MJ; Chin RFM Expert Rev Neurother; 2024 Mar; 24(3):235-249. PubMed ID: 38315124 [TBL] [Abstract][Full Text] [Related]
7. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Conry JA; Ng YT; Kernitsky L; Mitchell WG; Veidemanis R; Drummond R; Isojarvi J; Lee D; Paolicchi JM; Epilepsia; 2014 Apr; 55(4):558-67. PubMed ID: 24580023 [TBL] [Abstract][Full Text] [Related]
9. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K; Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273 [TBL] [Abstract][Full Text] [Related]
10. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Thiele E; Marsh E; Mazurkiewicz-Beldzinska M; Halford JJ; Gunning B; Devinsky O; Checketts D; Roberts C Epilepsia; 2019 Mar; 60(3):419-428. PubMed ID: 30740695 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Patel AD; Mazurkiewicz-Bełdzińska M; Chin RF; Gil-Nagel A; Gunning B; Halford JJ; Mitchell W; Scott Perry M; Thiele EA; Weinstock A; Dunayevich E; Checketts D; Devinsky O Epilepsia; 2021 Sep; 62(9):2228-2239. PubMed ID: 34287833 [TBL] [Abstract][Full Text] [Related]
12. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy. Perry MS Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420 [TBL] [Abstract][Full Text] [Related]
13. Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience. Wheless JW; Isojarvi J; Lee D; Drummond R; Benbadis SR Epilepsy Behav; 2014 Dec; 41():47-52. PubMed ID: 25282105 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive scoping review of fenfluramine's role in managing generalized tonic-clonic seizures in developmental and epileptic encephalopathies. Gil-Nagel A; Cross JH; Devinsky O; Ceulemans B; Lagae L; Knupp K; Schoonjans AS; Ryvlin P; Thiele EA; Polega S; Lothe A; Nabbout R Epilepsia; 2024 Aug; 65(8):2186-2199. PubMed ID: 39030735 [TBL] [Abstract][Full Text] [Related]
15. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice. Wirrell EC; Lagae L; Scheffer IE; Cross JH; Specchio N; Strzelczyk A Epilepsia Open; 2024 Oct; 9(5):1643-1657. PubMed ID: 38962968 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A; Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635 [TBL] [Abstract][Full Text] [Related]
17. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA). Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234 [TBL] [Abstract][Full Text] [Related]